(Press-News.org) In a comparison of treatments for maintaining remission of a certain type of vasculitis (inflammation of blood vessels), the immunosuppressant mycophenolate mofetil, regarded as an alternative to the drug often used to prevent relapse, azathioprine, was less effective, according to a study that will appear in the December 1 print edition of JAMA. The study is being released early online to coincide with its presentation at the American College of Rheumatology annual scientific meeting.
"Relapses of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) occur in 50 percent of patients within 5 years of diagnosis, and treatment toxicity is common. Safe and effective therapies to maintain remission of AAV are a priority," the authors write. "In AAV, small observational studies and randomized controlled trials reported successful remission induction and remission maintenance with mycophenolate mofetil. Whether mycophenolate mofetil is more effective than azathioprine [an immunosuppressive] for preventing relapses in AAV is uncertain."
Thomas F. Hiemstra, M.D., M.R.C.P., of the University of Cambridge and Lupus and Vasculitis Unit, Addenbrookes Hospital, Cambridge, England, and colleagues examined whether mycophenolate mofetil reduces the risk of relapse compared with azathioprine in patients with AAV in remission, and compared the risk of serious adverse events between treatment groups. The randomized trial was conducted at 42 centers in 11 European countries between April 2002 and January 2009. Eligible patients had newly diagnosed AAV and were ages 18 to 75 years at diagnosis. Patients were randomly assigned to receive azathioprine or mycophenolate mofetil after induction of remission with the agents cyclophosphamide and prednisolone.
A total of 156 patients were assigned to azathioprine (n = 80) or mycophenolate mofetil (n = 76) and were followed up for a median (midpoint) of 39 months. The researchers found that relapses were more common in the mycophenolate mofetil group (42/76 patients; 18 with major and 24 with minor relapses) compared with the azathioprine group (30/80 patients; 10 with major and 20 with minor relapses).
Severe adverse events did not differ significantly between groups, with 22 severe adverse events in 13 patients (16 percent) in the azathioprine group and 8 severe adverse events in 8 patients (7.5 percent) in the mycophenolate mofetil group. There were 8 severe infections in 8 patients in the azathioprine group and 3 severe infections in 3 patients in the mycophenolate mofetil group.
The secondary outcomes of Vasculitis Damage Index, estimated glomerular filtration rate (a measure of kidney function), and proteinuria (the presence of excessive protein in the urine) did not differ significantly between groups.
"Although mycophenolate mofetil is frequently regarded as a potent alternative to azathioprine, we found no evidence to support its use as the initial remission maintenance therapy for patients with AAV," the authors write.
(JAMA. 2010;304[21]:doi:10.1001/jama.2010.1658. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Therapeutic Interventions for Systemic Vasculitis
In an accompanying editorial, Gary S. Hoffman, M.D., M.S., of the Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University, Cleveland, writes that at this time, several key therapeutic findings regarding vasculitis research are apparent.
"Remission maintenance therapies (methotrexate, azathioprine) are as effective as prolonged cyclophosphamide and are much safer. Mycophenolate mofetil is associated with a higher relapse rate than azathioprine. Discontinuation of maintenance therapies appears to be associated with a higher rate of relapse than continuation of treatment. However, the risk-benefit formulas of long-term maintenance therapy vs. discontinuation and treatment of relapses require further study. Ideally these questions can be addressed by clinical trials of similar quality and importance as the report by Hiemstra et al and other major contributions of the European Vasculitis Study Group."
(JAMA. 2010;304[21]:doi:10.1001/jama.2010.1676. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
To contact Thomas F. Hiemstra, M.D., M.R.C.P., email tfh24@cam.ac.uk. To contact editorial author Gary S. Hoffman, M.D., M.S., call Brian Kolonick at 216-444-0898 or email kolonib@ccf.org.
###For More Information: Contact the JAMA/Archives Media Relations Department at 312-464-JAMA or email: mediarelations@jama-archives.org.
END
Relationships with drug manufacturers, device companies and other medical companies appear to be have decreased since 2004 but remain common among physicians, according to a report in the November 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
"The medical profession has embraced the importance of placing patient welfare ahead of financial benefits to physicians in clinical decision making," the authors write as background information in the article. "One tenet of medical professionalism is managing conflicts of interest related to physician-industry ...
Beginning dialysis therapy earlier in the development of advanced kidney disease appears to be associated with a greater risk of death for some patients in the following year, according to a report posted online today that will be published in the March 14 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Dialysis—a procedure in which a machine performs the blood-filtering functions of the kidneys—should help patients with advanced kidney disease live longer, reduce their illness burden and improve their quality of life, according to background ...
Potential gender differences in clinical management are under-researched. A systematic analysis of the incorporation of sex and gender into research design, published in the open access journal BMC Medicine, has found that, although there has been a progressive improvement since the 90s, there exists a striking under-representation of research about gender differences in patient management.
Sabine Oertelt-Prigione, from the Institute of Gender in Medicine, Berlin, worked with a team of researchers to study almost 9000 research articles, looking for evidence of sex and ...
Long delays between developing symptoms and going to the hospital are common among patients with a certain type of heart attack, according to a report in the November 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Professional guidelines recommend that patients call 9-1-1 if symptoms suggestive of a heart attack do not improve within five minutes, according to background information in the article. Medical treatment is most urgent in patients with ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram ...
A new cognitive assessment tool with 16 items appears potentially useful for identifying problems in thinking, learning and memory among older adults, according to a report posted online today that will be published in the March 14 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
An estimated 3.4 million older adults in the United States have dementia, and an additional 5.4 million have milder forms of cognitive impairment, according to background information in the article. "For many older adults, cognitive impairment contributes to loss ...
Patients with stroke who experience improvement within one hour of receiving the clot-dissolving medication tissue plasminogen activator appear more likely to do well three months later, according to a report in the November issue of Archives of Neurology, one of the JAMA/Archives journals.
Only one effective therapy has been approved for acute ischemic stroke (in which blood flow to an area of the brain is blocked or reduced), according to background information in the article. Within 4.5 hours of developing symptoms, patients receive an intravenous (IV) dose of the ...
Long-term, regular use of vitamins E and C has no apparent effect on the risk of age-related cataract in men, according to a report in the November issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
"An estimated 20.5 million persons 40 years and older in the United States show some evidence of age-related cataract," the authors write as background information in the article. "Because oxidative damage is a prominent feature of cataracts, one focus of nutrition research has been the link between dietary intake of nutrients with antioxidant potential, ...
Corneal arcus, a condition in which a ring of lipids builds up around the cornea, appears common among middle-age and older adults and may be associated with elevated eye pressure, according to a report in the November issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Intraocular pressure (the pressure inside the eye) is the only treatable risk factor for glaucoma, the leading cause of irreversible blindness worldwide, according to background information in the article. "The accuracy of intraocular pressure measurement is crucial in the diagnosis ...
MIAMI - A new study led by scientists at the University of Miami Rosenstiel School of Marine and Atmospheric Science suggests that over the next century recruitment of new corals could drop by 73 percent, as rising CO2 levels turn the oceans more acidic. The research findings reveal a new danger to the already threatened Caribbean and Florida reef Elkhorn corals.
"Ocean acidification is widely viewed as an emerging threat to coral reefs," said Rosenstiel School graduate student Rebecca Albright. "Our study is one of the first to document the impacts of ocean acidification ...
A new solar-powered device to measure blood pressure may help slow the worldwide increase in cardiovascular disease by providing affordable and reliable blood pressure testing in low income countries, according to research published in Hypertension: Journal of the American Heart Association.
The solar powered device — 94 percent in agreement with the standard blood pressure testing method for systolic blood pressure — is in field testing in Uganda and Zambia, Africa.
"The incidence of hypertension is rising dramatically in these countries," said Eoin O'Brien, M.D., ...
